Background-Transthyretin familial amyloid polyneuropathy is a hereditary form of amyloidosis characterized by sensorimotor and autonomic neuropathy, cardiac conduction defects, and infiltrative cardiomyopathy. Previous studies have suggested that myocardial sympathetic denervation assessed by 123-iodine metaiodobenzylguanidine (MIBG) imaging occurs early in disease progression. However, its prognostic significance was never evaluated. We aimed to study the long-term prognostic value of myocardial sympathetic denervation detected by MIBG imaging in transthyretin familial amyloid polyneuropathy.
F amilial amyloid polyneuropathy (FAP) is a rare and fatal systemic disease resulting from autosomally dominant inherited single-point mutations in the transthyretin (TTR) gene. More than 100 single-nucleotide polymorphisms of TTR have been identified with clinical phenotype expression varying greatly by mutation. 1 Some forms affect almost exclusively the heart, whereas others are predominantly neuropathic (with or without associated cardiac involvement). V122I variant, the most common mutation in blacks, induces cardiac amyloidosis. 2 In contrast, the V30M variant is characterized by progressive sensory-motor and autonomic neuropathy and myocardial involvement being a late manifestation of the disease. [3] [4] [5] The V30M TTR-FAP was first described in families from Portugal by Andrade 6 but is also common in Japan and Sweden. The penetrance and age of onset vary among and within populations. In Portugal, the penetrance is high (at least 80%) and symptoms develop before the age of 40 years leading to death in 10 to 15 years. 5 However, late-onset cases and older asymptomatic carriers have also been identified. 7 Initial symptoms are often difficult to recognize because they are predominantly related to the involvement of small nerve fibers, causing loss of thermal and pain sensation and dysautonomic abnormalities. 8 At the time clinical manifestations occur, nerve fiber dysfunction and amyloid infiltration in several organs are already established.
Because TTR is predominantly synthesized in the liver, orthotopic liver transplantation has been widely used in an attempt to halt or at least attenuate the disease progression. 9 The majority of symptoms will not regress after the procedure, and therefore, there is a consensual agreement that it should be performed early in the disease. 9, 10 Several reports suggest that prior significant myocardial amyloid deposition will progress after transplantation, 11 with a negative prognostic impact. 12 Thus, the early identification of the disease and the accurate prognostic stratification of individuals with V30M TTR mutation would be of particular clinical relevance to implement timely therapeutic interventions.
Cardiovascular manifestations are mainly because of autonomic neuropathy (blood pressure [BP] and heart rate control disturbances) and cardiac amyloid deposition (infiltrative cardiomyopathy, arrhythmia, and conduction defects). 13 In contrast to other systemic amyloidosis, cardiac manifestations are not the dominant clinical picture in TTR-FAP. However, previous studies involving small groups of patients suggest that cardiovascular abnormalities may be detected at initial stages of the disease, sometimes preceding the neurological manifestations, offering an opportunity for early clinical diagnosis. 14, 15 123-iodine metaiodobenzylguanidine (MIBG) imaging is a noninvasive tool for assessing myocardial sympathetic innervation. Some studies suggested that myocardial sympathetic denervation often precedes the neurological 16 and cardiac 16, 17 manifestations of the V30M TTR-FAP disease. In the context of ischemic and nonischemic cardiomyopathies, it has been shown that late heart-to-mediastinum MIBG uptake ratio (H/M) below the lower limit of normal (1.60) is a strong independent predictor of adverse outcome. [18] [19] [20] However, the survival prognostic value of MIBG imaging in V30M TTR-FAP has remained unknown.
This study aims to provide a prospective validation of the prognostic value of MIBG imaging and to compare it with other methods for cardiovascular and neurological evaluation in V30M TTR-FAP.
Methods
This is a longitudinal study of consecutive individuals with V30M TTR mutation referred for cardiovascular evaluation between September 1998 and December 2010. V30M TTR mutation was confirmed by genetic analysis. In addition to neurological evaluation, all subjects underwent ECG, Holter recording, ambulatory blood pressure monitoring (ABPM), conventional echocardiography, and 123-I MIBG imaging at the time of the first clinical evaluation.
Neurological Evaluation
A validated clinical scale which included motor and sensory function, autonomic symptoms and weight was applied to detect and quantify neurological symptoms. 21 The clinical scale was scored from 0 to 100 (maximal abnormality).
A neurophysiological score (NP) was calculated from standardized nerve conduction studies and needle electromyography. 21, 22 The NP score was quantified from 0 to 100 (maximal abnormality; Table I in the online-only Data Supplement). Neurological involvement was defined by the presence of any neurophysiological abnormality. Subjects without neurological involvement at the time of enrollment were considered asymptomatic carriers. Patients with neurological disability were classified according to the NP score tertile distribution and were considered to have mild neurological involvement if the NP score was <20 and moderate-to-severe disability if the NP score was ≥20 (third tertile).
Cardiovascular Evaluation
A 24-hour 3-channel ambulatory ECG recording was performed with a SyneScope version 3.10 Holter monitoring system (Sorin Group). Holter abnormality was defined by the presence of one of the following criteria: left bundle-branch block; AV block ≥second degree; pacemaker rhythm; premature atrial or ventricular contractions ≥240/24 hour; and supraventricular or ventricular arrhythmias. Heart rate variability analysis was performed in the last 103 patients who were in sinus rhythm. Time and frequency domain indices were measured as previously described. 23 ABPM measurements were performed using SpaceLabs 90207 monitors (Healthcare, Inc) as described elsewhere. 24 Daytime, nighttime, and circadian systolic BP variation were determined. High BP was classified as mean daytime BP≥140/90 mm Hg or nighttime BP≥125/75 mm Hg. 25 The nondipper pattern was defined as nocturnal systolic BP drop <10% and the reverse dipper pattern as systolic BP higher at night. ABPM abnormality was identified by the presence of high BP, nondipper, or reverse dipper patterns.
Echocardiography was performed using the GE Vivid 7 system since 2007 and its precursor beforehand. End-diastolic interventricular septal and posterior wall thicknesses, left ventricle (LV) diameter, LV fractional shortening, and mitral inflow E/A ratio were measured as previously described. 16 LV wall thickness was defined by the mean of the septal and posterior wall thicknesses and was considered increased if ≥12 mm. Mitral inflow E/A ratios <1.0 or >2.5 were considered abnormal.
123-I MIBG Imaging
Subjects were pretreated with an iodine solution to block uptake of free iodine (123-I) by the thyroid gland. Ten minutes planar images were acquired from an anterior thoracic view (256×256), 15 minutes (early imaging) and 3 hours (late imaging) after the IV injection of 185 MBq of 123-I MIBG. Imaging was performed using a dual-head camera system (Millenium, General Electric Healthcare) equipped with a low-energy, high-resolution parallel-hole collimator. A 20% energy window was centered over the 159 keV photopeak of 123-I. The H/M was determined dividing the average counts per pixel in a manually drawn region of interest placed over the heart by the average counts per pixel in the upper mediastinum. The myocardial MIBG washout rate from early to late imaging was calculated using the formula: ([early H/M−late H/M]/early H/M)×100. No background correction was performed. The H/M was considered reduced if below than 1.60, the estimated lower limit of normal. [18] [19] [20] 
Clinical Follow-Up
All subjects included in this cohort underwent annual cardiovascular evaluation as described above.
Participation in the study required informed consent. The study's protocol complied with the Declaration of Helsinki and was approved by the ethics committee of the Santa Maria University Hospital.
Statistical Analysis
Continuous variables with normal distribution (daytime and nighttime systolic and diastolic BP, nocturnal systolic BP drop, LV wall thickness, early H/M, late H/M, and washout rate) were expressed as the mean±SD and were compared using Student t/ANOVA tests. Non-normally distributed continuous variables (age, NP and clinical scores, number of premature atrial and ventricular contractions, and mitral E/A ratio) were reported as median and interquartile range and were compared using Mann-Whitney/Kruskal-Wallis tests. Categorical variables (presence of late-onset disease, neurological involvement, cardiovascular involvement, late H/M <1.60, and abnormalities in ECG, Holter, ABPM, or echo) were described as the percentages of the cohort and were compared using Fisher exact tests. Late H/M was correlated with NP score using the Pearson coefficient.
The end point of the study was all-cause mortality. The primary analysis was on the basis of subjects classified into 2 prespecified groups, late H/M <1.60 and late H/M ≥1.60. [17] [18] [19] Univariate Cox proportional hazards model fitted to the time to end point was applied to test our hypothesis. Additional univariate Cox proportional hazards analyses were performed using the following continuous numeric variables: NP and clinical scores, day-and nighttime BP, percentage of systolic BP drop at night, LV wall thickness, mitral inflow E/A ratio, total number of premature atrial and ventricular contractions during 24 hours, early and late H/M MIBG uptake, and washout rate. The accuracy for predicting all-cause mortality based on the Cox proportional cumulative hazard ratio was determined by the area under the receiver operating characteristic curve. For early and late H/M, the hypothesis that lower values are associated with higher event risk (all-cause mortality) was tested. Additional multivariate Cox proportional hazards analyses were performed to identify and account for significant predictors of the clinical outcome. To avoid over fitting, nonsignificant predictor variables were removed from the model in a stepwise forward conditional fashion (P value cut-off for entry=0.05 and for removal=0.10).
To test the prognostic impact of liver transplantation, a nested casecontrol analysis of the post-transplant survival was performed. For each transplanted patient, a control was selected for matching the NP score determined just before transplantation.
Cumulative event rates were assessed using the method of Kaplan-Meier and log-rank test. Hazard ratios were calculated considering the complete duration of follow-up. The cumulative mortality rates were determined at the fifth year after inclusion (median follow-up duration). All analyses were 2-sided and a P value <0.05 was considered statistically significant. Statistical analysis was performed using the SPSS software package, version 20.0 (SPSS Inc, Chicago, IL).
Results

Study Population
Of the 169 individuals with V30M TTR mutation evaluated, 26 were excluded because they did not complete all cardiac exams at enrollment. No other exclusion criteria were considered. The final population comprised 143 individuals with a median age of 42 years (range, 19-84). The clinical characteristics of the population are summarized in Table 1 . Neurological involvement was present in 75 patients (52.4%), and 55 participants (38.5%) reported cardiovascular symptoms. The median age at the time of clinical presentation was 46 years (range, 33-60), and 48 patients (33.6%) had late onset of disease (age ≥50 years). Sixty-eight individuals (47.6%) had no neurophysiological abnormalities and were considered asymptomatic carriers.
Cardiovascular abnormalities identified by the ECG, Holter recording, ABPM, and echocardiography were present in 102 subjects (71.3%) and did not differ between the sexes. The most frequent cardiovascular abnormality was observed in the circadian BP profile and included the nondipper (34.3%) and the reverse dipper (10.5%) patterns. Echocardiography showed normal systolic function in all patients. The mean LV wall thickness was 10±2 mm (range, 7-18). In 33 patients (23%), the wall thickness was >12 mm and in 11 of them, it was >15 mm. Only one patient had a restrictive mitral inflow pattern (E/A ratio>2.5). Holter monitoring revealed abnormalities in 45 patients (31.5%), including nonsustained ventricular tachycardia in 4 patients and sustained atrial arrhythmias in 2 patients.
Cardiovascular Abnormalities According to Neurological Involvement
Cardiovascular abnormalities were present in 96% of patients with neurological involvement and their prevalence increased with the severity of neurological disability. However, 46% of asymptomatic carriers already had cardiovascular abnormalities as illustrated in Figure 1 . The comparison of data from ECG, Holter, ABPM, echocardiography, MIBG imaging, and heart rate variability analysis between asymptomatic carriers and patients with neurological involvement is presented in Tables II and III in 
Prognostic Analysis
Over a median follow-up of 5.5 years, 32 deaths occurred (22.4%), 10 among liver transplanted patients. The cause of death was directly related to TTR-FAP in 90% of the cases (Table VI in the online-only Data Supplement). Table 2 shows the comparison of patients' clinical characteristics on the basis of the occurrence of death and the univariate analyses of their association with prognosis. Mortality did not differ by sex. Patients with late-onset disease had a higher mortality (Hazard Ratio [HR], 2.52; 95% CI, 1.25-5.01; P=0.010). However, after adjustment for age, patients with early-onset disease were the ones at higher risk for adverse prognosis (HR, 3.30; 95% CI, 1.15-9.47; P=0.026). Patients who died were more likely to have higher clinical and NP scores, to present more severe cardiovascular abnormalities and to have lower late H/M. Heart rate variability indices did not discriminate prognosis.
To explore the prognostic value of the neurological and cardiovascular abnormalities in TTR-FAP patients, we conducted Kaplan-Meier survival analyses ( Figures 3A, 4 Figure 3A ). Survival analysis showed that 5-year event rates were 42% for patients with late H/M <1.60 versus 7.4% for those with late H/M ≥1.60. Treated as a continuous variable, there was a progressive decline in the 5-year mortality from 53.8% for late H/M <1.20 to 5.0% for late H/M ≥1.80 (P<0.001; Figure 3B ).
The risk of death also increased with the NP score. This association was largely attributable to the ominous outcome of patients with advanced neurological involvement (NP score≥20: HR, 17.18; 95% CI, 4.84-61.0; P<0.001; Figure 4A ). Similarly, patients belonging to the third tertile distribution of the clinical score had higher mortality (HR, 10.26; 95% CI, 3.29-32.04; P<0.001), but lower scores did not discriminate prognosis ( Figure 4B ). The risk of all-cause mortality was ≈3× higher in patients with ECG abnormalities (HR, 2.97; 95% CI, 1.27-6.93; P=012) or Holter abnormalities (HR, 3.57; 95% CI, 1.73-7.36; P=0.001; Figure 5A and 5B). On ABPM findings, only high BP (HR, 3.61; 95% CI, 1.76-7.40; P<0.001) and the reverse dipper pattern (HR, 3.22; 95% CI, 1.36-7.64; P=0.008) were associated with mortality ( Figure 5C ). In respect to echocardiography, LV wall thickening (≥12 mm; HR, 3.79; 95% CI, 1.69-7.61; P<0.001) and abnormal mitral E/A ratio (HR, 2.71; 95% CI, 1.35-5.45; P=0.005) were identified as prognostic markers with an even worse outcome in patients with both changes ( Figure 5D ). Table 3 shows the results of univariate and multivariate analysis in the prediction of mortality. The only independent prognostic predictors were age and late H/M. The accuracy of the combination of age and late H/M in predicting mortality was moderate (area under the receiver operating characteristic curve: 0.72±0.1; 95% CI, 0.61-0.82; P<0.001; Figure III in the online-only Data Supplement).
Liver Transplantation
Candidates for liver transplantation were patients with documented neurological involvement but without end-stage disease who were willing to be transplanted. The decision to transplant was based on the neurological evaluation and was not dictated by the cardiovascular assessment or MIBG imaging. At the time of initial evaluation, most individuals were asymptomatic or mildly symptomatic and were not yet considered candidates. During follow-up, 53 patients (36.4%) were submitted to liver transplant that was performed after a median period of 2.8 years (interquartile range, 1. 2-5.4) . No patient died while waiting for the transplant. The surgical-related mortality was 11.3% (6 out of 53 patients).
To examine the prognostic impact of liver transplantation, we performed a nested case-control analysis of the posttransplant survival. This method intended to prevent the bias produced by the existence of a large number of subjects without neurological involvement in the group of nontransplanted patients, and therefore, not candidates to liver transplant. Because the decision to transplant was based on the neurological evaluation, for each of the 53 transplanted patients, a control was selected for matching the NP score determined before transplantation. Survival was analyzed from the date of transplantation. The 2 groups were perfectly matched to the NP score and no significant differences were observed in their age, clinical score, or late H/M uptake (Table VII in There was a significantly better survival in transplanted patients in comparison with NP score-matched control patients (HR, 0.39; 95% CI, 0.16-0.92; P=0.032; Figure 6A ). Survival analysis showed that 5-year event rates were 4.8% 50  49  40  36  30  26  23  19  14  14  11  9  3  1  Clinical score 1-14  45  43  40  31  25  20  16  9  6  4  3  2  1  0  Clinical score ≥15  48  42  39  30  23  17  13  8 for transplanted patients versus 33.9% for nontransplanted patients. The long-term mortality after the procedure significantly differed according to the late H/M assessed before transplantation. Patients with late H/M <1.60 were at higher risk of unfavorable outcome; however, they still benefited from the procedure ( Figure 6B ).
Discussion
This is the largest prospective study of symptomatic and asymptomatic V30M TTR mutation carriers that explored the prognostic significance of multiple methods for cardiovascular and neurological evaluation. The most relevant findings are: (1) cardiovascular abnormalities may antedate the neurological involvement; and (2) cardiac sympathetic denervation as assessed by late H/M MIBG imaging is a valuable prognostic marker in TTR-FAP. The availability of genetic screening for TTR-FAP patients' relatives enabled us to evaluate the cardiovascular involvement not only in symptomatic patients, but also in a large sample of V30M TTR mutation carriers at preclinical or very early stages of the disease. We confirmed that cardiovascular abnormalities are common in V30M TTR-FAP, particularly in patients with neurological involvement. However, this study also revealed that morphological or functional cardiovascular abnormalities are already present in more than a third of the asymptomatic carriers, suggesting the need for a systematic multiorgan evaluation to identify the onset of disease. Cardiovascular abnormalities included manifestations of autonomic dysfunction (impairment of circadian BP variation and cardiac sympathetic denervation as assessed by MIBG) and manifestations of amyloid deposition in the heart (arrhythmias, conduction defects, and morphological evidence of myocardial infiltration). As in other studies, abnormalities in circadian BP variation were frequently detected. 26, 27 High BP and the decrease in nocturnal systolic BP drop were the most common cardiovascular abnormalities and were more pronounced in patients with neurological involvement.
With regard to echocardiographic characterization, a significant increase in LV wall thickness has been described with disease progression. 28 However, cardiac infiltration in V30M TTR-FAP is not as pronounced as that observed in other forms of amyloidosis and the manifestations of restrictive cardiomyopathy are quite unusual. In our study, only 33 patients (23%) had LV wall thickening ≥12 mm and just one third of them (11 patients) are >15 mm. These patients were older and had more advanced stages of the disease. Rhythm disturbances and conduction defects are frequent consequences of cardiac amyloidal infiltration. Such as other studies, 14, 26 we observed an increase in their occurrence with the worsening of TTR-FAP. It has been suggested that conduction defects can be relatively dissociated from LV thickening 14 and may even worsen after liver transplantation. 29 Our study documented the prognostic relevance of the cardiovascular involvement in TTR-FAP. Abnormalities in the ECG, Holter, ABPM, and echocardiogram were associated with higher long-term mortality but were not independent prognostic markers. We must recognize that this study is not powered to exclude the potential benefit of such risk markers. What our data suggest is that abnormalities in these A B 
Myocardial Sympathetic Denervation in V30M TTR-FAP
In this study, the late H/M was significantly lower in patients with neurological compromise as compared with the asymptomatic carriers. In addition, the severity of neurological disability correlated with the decrease of myocardial MIBG uptake. In a pioneer study using MIBG imaging in 12 V30M TTR-FAP Japanese patients, Tanaka et al 16 demonstrated that myocardial denervation may occur before the development of LV thickening or clinically apparent heart disease. In another study of 17 V30M TTR-FAP patients, it was shown that the reduction of late H/M correlates with the severity of polyneuropathy. 17 Our study demonstrated for the first time that MIBG imaging is useful for prognostic stratification of TTR-FAP patients. In fact, as the late MIBG decreased, long-term prognosis deteriorated. To examine the prognostic value of late H/M, we tested the cut-off of 1.60 based on previous studies of heart failure patients. [18] [19] [20] We observed that the risk of death during follow-up was 7× higher in patients with late H/M <1.60.
The identification of patients at risk of death and the selection of candidates for the available or future treatments should be based, as far as possible, on precise criteria. Our data confirms that symptoms are quite imprecise, particularly in the early stages of the disease. In fact, the clinical score was not an independent prognostic predictor. Our results also suggest that prognostic stratification of TTR-FAP patients should consider not only the neurological evaluation, but also the MIBG imaging.
We conducted a nested case-control analysis of the posttransplant survival to investigate whether liver transplantation improves the outcome of TTR-FAP patients and to explore the potential value of MIBG imaging in the patients' selection. A significant increase in survival was noted in transplanted patients as compared with controls. Patients with late H/M <1.60 were at higher risk of ominous prognosis. However, patients with late H/M <1.60 without end-stage neurological disability, who were submitted to liver transplant, seemed to have benefited from the procedure. We must recognize that the number of patients included in the nested case-control analysis is small and precludes definitive conclusions about the benefit of liver transplantation in patients with late H/M <1.60. Delahaye et al 30 performed MIBG imaging in 31 patients before and after liver transplantation. The H/M MIBG uptake was decreased before transplant and did not improve after the procedure. In addition, they suggested that patients with severe pretransplant cardiac sympathetic denervation have neurological deterioration after transplantation, but the prognostic impact of MIBG imaging was not assessed. In this analysis, we did not evaluate the progression of the neurological disability or cardiac sympathetic denervation after transplant.
Limitations
We observed that patients with neurological involvement and late H/M <1.60 submitted to liver transplantation were at higher risk of unfavorable outcome but seemed to have benefited from the procedure. Despite the prognostic value of MBIG, we must be cautious about its role in the decision to transplant. In fact, no patient was transplanted based on the MIBG results. To test the added value of late H/M in the decision-making, it would be necessary to perform a randomized controlled trial what seems very difficult given the rarity of the disease. In the nested case-control analysis, we compared the post-transplant survival of patients submitted to liver transplantation with the prognosis of nontransplanted patients perfectly matched to the NP score. Despite the absence of statistically significant differences in the demographic characteristics of the 2 groups, control patients tended to be slightly older what may have had impact in the results.
In this study, full cardiac evaluation was repeated annually during follow-up but only the initial evaluation and the one before liver transplantation were analyzed. In fact, we did not evaluate the prognostic significance of the changes in repeated cardiovascular exams.
This investigation includes the largest series of asymptomatic V30M TTR mutation carriers. In this subpopulation, the event rate during follow-up was very low. Actually, the majority of deaths occurred in patients with neurological involvement, and therefore, these were the ones that contributed the most to the prognostic analysis. It would be important to identify prognostic predictors specifically in asymptomatic carriers, but this is not possible with the present follow-up duration.
Finally, we must emphasize that our findings are valid for V30M TTR-FAP and should not be extrapolated to other variants of TTR-FAP.
